Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
piromidic acid
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Piromidic acid is a synthetic quinolone antibiotic belonging to the pyridopyrimidine class. It exhibits antibacterial activity primarily against gram-negative bacteria and is used in the treatment of urinary tract and intestinal infections. Its mechanism of action involves inhibition of bacterial DNA synthesis, making it effective as a DNA synthesis inhibitor. Piromidic acid acts by interfering with bacterial enzymes involved in DNA replication, similar to other quinolone antibiotics[1][3][4][6]. The drug has been approved for use but has also been withdrawn in some regions[3].
- Brand names
- BactramylPanacidEnterolPiramanid
- Other names
- piromidic acid19562-30-2
02
Targets
DNA gyraseTopo IV (Bacterial Topoisomerase IV)
Beyond the preview
Go deeper on piromidic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on piromidic acid.